Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, Manfrini M, McNamara J, Robertson DS, Stokmaier D, Wendt JK, Winthrop KL, Traboulsee A. Bar-Or A, et al. Among authors: winthrop kl. Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29. Neurology. 2020. PMID: 32727835 Free PMC article. Clinical Trial.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, Kappos L. Hauser SL, et al. Mult Scler. 2022 Sep;28(10):1576-1590. doi: 10.1177/13524585221079731. Epub 2022 Mar 1. Mult Scler. 2022. PMID: 35229668 Free PMC article. Clinical Trial.
Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial.
Winthrop KL, Skolnick AW, Rafiq AM, Beegle SH, Suszanski J, Koehne G, Barnett-Griness O, Bibliowicz A, Fathi R, Anderson P, Raday G, Eagle G, Ben-Yair VK, Minkowitz HS, Levitt ML, Gordon MS. Winthrop KL, et al. Open Forum Infect Dis. 2022 May 11;9(7):ofac232. doi: 10.1093/ofid/ofac232. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35832268 Free PMC article.
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
Lange C, Böttger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL; expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases. Lange C, et al. Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25. Lancet Infect Dis. 2022. PMID: 35090639 Review.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. Griffith DE, et al. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST. Am J Respir Crit Care Med. 2007. PMID: 17277290 Review. No abstract available.
313 results